CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) indication: heart failure, NYHA class II to III.
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ivabradine hydrochloride (ivabradine) be reimbursed for the treatment of stable chronic heart failure to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
May 24, 2017, 2017
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that ivabradine hydrochloride (ivabradine) be reimbursed for the treatment of stable chronic heart failure to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with standard chronic heart failure therapies |
|---|---|
| Physical Description: | 1 PDF file (7 pages) |